Company Overview: SNY

SNY Overview

Upcoming Projects (SNY)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (SNY)

Discussing the current treatment available in the ALS landscape including Rilutek, Radicava and Qalsody
Tickers: BIIB, SNY, MTPA
Executed On: Dec 10, 2024 at 10:00 AM EST
FDA Approval of isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma
Ticker: SNY
Executed On: Nov 08, 2024 at 05:00 PM EST
A Third Look: Checking in on the prescription trends of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease
Tickers: AZN, SNY
Executed On: Nov 06, 2024 at 04:30 PM EST
A Second Look: Checking in on the prescription trends of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease
Tickers: AZN, SNY
Executed On: Nov 04, 2024 at 01:00 PM EST
Checking in on the prescription trends of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease
Tickers: AZN, SNY
Executed On: Oct 30, 2024 at 11:30 AM EDT
A Third Look: Discussing the use of Dupixent® (dupilumab) for children aged 1 and older with Eosinophilic Esophagitis (EoE)
Ticker: SNY
Executed On: Oct 17, 2024 at 01:30 PM EDT
A Second Look: Discussing the use of Dupixent® (dupilumab) for children aged 1 and older with Eosinophilic Esophagitis (EoE)
Ticker: SNY
Executed On: Oct 07, 2024 at 06:00 PM EDT
Discussing the current landscape of the seasonal flu, COVID-19, and various vaccinations.
Tickers: GSK, SNY, AZN
Executed On: Oct 01, 2024 at 10:00 AM EDT
Third View: Discussing Dupixent's recent Phase 3 results showing significant improvements in itch and hives for patients with Chronic Spontaneous Urticaria (CSU).
Ticker: SNY
Executed On: Oct 01, 2024 at 09:00 AM EDT
Discussing the use of Dupixent® (dupilumab) for children aged 1 and older with Eosinophilic Esophagitis (EoE)
Ticker: SNY
Executed On: Sep 30, 2024 at 03:00 PM EDT
Second View: Discussing Dupixent's recent Phase 3 results showing significant improvements in itch and hives for patients with Chronic Spontaneous Urticaria (CSU).
Ticker: SNY
Executed On: Sep 24, 2024 at 04:30 PM EDT
Discussing Dupixent's recent Phase 3 results showing significant improvements in itch and hives for patients with Chronic Spontaneous Urticaria (CSU).
Ticker: SNY
Executed On: Sep 19, 2024 at 08:00 AM EDT
A Third Look: Digging into the phase 3 HERCULES clinical trial of tolebrutinib in patients with non-relapsing secondary progressive multiple sclerosis.
Ticker: SNY
Executed On: Sep 12, 2024 at 10:30 AM EDT
A Third Perspective: Checking in with a prescriber of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease.
Tickers: AZN, SNY
Executed On: Sep 11, 2024 at 01:00 PM EDT
A Second Look: Digging into the phase 3 HERCULES clinical trial of tolebrutinib in patients with non-relapsing secondary progressive multiple sclerosis.
Ticker: SNY
Executed On: Sep 09, 2024 at 05:00 PM EDT
A Second Perspective: Checking in with a prescriber of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease.
Tickers: AZN, SNY
Executed On: Sep 06, 2024 at 01:30 PM EDT
Digging into the phase 3 HERCULES clinical trial of tolebrutinib in patients with non-relapsing secondary progressive multiple sclerosis.
Ticker: SNY
Executed On: Sep 05, 2024 at 10:00 AM EDT
Checking in with a prescriber of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease.
Tickers: AZN, SNY
Executed On: Aug 26, 2024 at 01:00 PM EDT
A Third Look: Discussing the potential of Dupixent (dupilumab) for COPD and the recent updated results from the Phase 3 trial published on May 20th.
Tickers: REGN, SNY
Executed On: May 23, 2024 at 03:00 PM EDT
A Second Look: Discussing the potential of Dupixent (dupilumab) for COPD and the results from the Phase 3 NOTUS trial.
Tickers: REGN, SNY
Executed On: May 21, 2024 at 09:00 AM EDT
A Third Look: Reviewing the LUNA 3 phase 3 study from Sanofi on their BTK inhibitor, Rilzabrutinib for immune thrombocytopenia
Ticker: SNY
Executed On: May 16, 2024 at 04:30 PM EDT
A Second Look: Reviewing the LUNA 3 phase 3 study from Sanofi on their BTK inhibitor, Rilzabrutinib for immune thrombocytopenia
Ticker: SNY
Executed On: May 15, 2024 at 04:00 PM EDT
Discussing the potential of Dupixent (dupilumab) for COPD and the results from the Phase 3 NOTUS trial.
Tickers: REGN, SNY
Executed On: May 13, 2024 at 01:00 PM EDT
Reviewing the LUNA 3 phase 3 study from Sanofi on their BTK inhibitor, Rilzabrutinib for immune thrombocytopenia
Ticker: SNY
Executed On: May 10, 2024 at 01:00 PM EDT
A Third Discussion: Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 25, 2024 at 05:15 PM EDT
A Second Discussion: Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 19, 2024 at 04:00 PM EDT
Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 17, 2024 at 04:30 PM EDT
A Second Look: Discussing the results from the Phase 2b study STREAM-AD of Amlitelimab for atopic dermatitis
Ticker: SNY
Executed On: Apr 16, 2024 at 09:00 AM EDT
A Third Look: Discussing the results from the Phase 2b study STREAM-AD of Amlitelimab for atopic dermatitis
Ticker: SNY
Executed On: Mar 20, 2024 at 03:30 PM EDT
Discussing the results from the Phase 2b study STREAM-AD of Amlitelimab for atopic dermatitis
Ticker: SNY
Executed On: Mar 19, 2024 at 08:00 AM EDT
A Third View: Discussing the recent results from the phase 2b STREAM-AD clinical trial of amlitelimab for atopic dermatitis presented at EADV 2023
Ticker: SNY
Executed On: Nov 08, 2023 at 04:30 PM EST
A Second View: Discussing the recent results from the phase 2b STREAM-AD clinical trial of amlitelimab for atopic dermatitis presented at EADV 2023
Ticker: SNY
Executed On: Nov 07, 2023 at 12:15 PM EST
Discussing the recent results from the phase 2b STREAM-AD clinical trial of amlitelimab for atopic dermatitis presented at EADV 2023
Ticker: SNY
Executed On: Nov 03, 2023 at 10:00 AM EDT
A Second View: Discussing the potential of an E. coli vaccine
Tickers: SNY, JNJ
Executed On: Oct 20, 2023 at 12:30 PM EDT
Discussing the potential of an E. coli vaccine
Tickers: SNY, JNJ
Executed On: Oct 12, 2023 at 11:30 AM EDT
Discussing potential of Sanofi's novel anti-CD40L antibody, frexalimab in patients with relapsing multiple sclerosis.
Ticker: SNY
Executed On: Sep 20, 2023 at 10:00 AM EDT
A Third View: Investigating the phase 2B data on amlitelimab, an anti-OX40-ligand monoclonal antibody for the treatment of atopic dermatitis being developed by Sanofi.
Ticker: SNY
Executed On: Sep 08, 2023 at 12:00 PM EDT
A Third Look: Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 31, 2023 at 12:00 PM EDT
A Second Look: Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 30, 2023 at 04:00 PM EDT
Examining how Kevzara® (sarilumab) fits into the treatment landscape for treating patients with Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 25, 2023 at 05:00 PM EDT
A Second View: Investigating the phase 2B data on amlitelimab, an anti-OX40-ligand monoclonal antibody for the treatment of atopic dermatitis being developed by Sanofi.
Ticker: SNY
Executed On: Aug 09, 2023 at 03:00 PM EDT
Investigating the phase 2B data on amlitelimab, an anti-OX40-ligand monoclonal antibody for the treatment of atopic dermatitis being developed by Sanofi.
Ticker: SNY
Executed On: Aug 03, 2023 at 09:15 AM EDT
A Third Opinion: Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatrician
Tickers: SNY, AZN
Executed On: Aug 01, 2023 at 09:00 AM EDT
A Second Opinion: Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Emergency Room Physician
Tickers: SNY, AZN
Executed On: Jul 20, 2023 at 02:00 PM EDT
Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Emergency Room Physician
Tickers: SNY, AZN
Executed On: Jul 19, 2023 at 12:00 PM EDT
Discussing the potential of enzyme replacement therapies such as Sanofi's Nexviazyme (avalglucosidase alfa-ngpt) and Amicus Therapeutics' Pombiliti + Opfolda (AT-GAA) in late-onset Pompe disease with a Genetic Counselor.
Tickers: FOLD, SNY
Executed On: Jul 13, 2023 at 01:00 PM EDT
Discussing enzyme replacement therapies such as Sanofi's Nexviazyme (avalglucosidase alfa-ngpt) and Amicus Therapeutics's Pombiliti + Opfolda(AT-GAA) with a specialist who treats patients with late-onset Pompe disease.
Tickers: FOLD, SNY
Executed On: Jun 13, 2023 at 11:00 AM EDT
A third look: Digging into the potential of Dupixent (dupilumab) in patients with COPD and the positive results from the Phase 3 BOREAS trial
Tickers: REGN, SNY
Executed On: Apr 06, 2023 at 06:00 PM EDT
A second look: Digging into the potential of Dupixent (dupilumab) in patients with COPD and the positive results from the Phase 3 BOREAS trial
Tickers: REGN, SNY
Executed On: Mar 31, 2023 at 10:00 AM EDT
Digging into the potential of Dupixent (dupilumab) in patients with COPD and the positive results from the Phase 3 BOREAS trial
Tickers: REGN, SNY
Executed On: Mar 30, 2023 at 04:00 PM EDT
A second look: Discussing the potential of KT-474 and it's Phase 1 results which provide the first clinical validation for targeting the IRAK4 pathway with a degrader in TLR/IL-1R-driven inflammatory diseases such as atopic dermatitis
Tickers: KYMR, SNY
Executed On: Jan 03, 2023 at 08:15 PM EST
Discussing the potential of KT-474 and it's Phase 1 results which provide the first clinical validation for targeting the IRAK4 pathway with a degrader in TLR/IL-1R-driven inflammatory diseases such as atopic dermatitis
Tickers: KYMR, SNY
Executed On: Dec 19, 2022 at 03:45 PM EST
A discussion on the Phase II/III study by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi investigating the safety and efficacy of single-dose acoziborole
Ticker: SNY
Executed On: Dec 06, 2022 at 12:00 PM EST
A Second look at the new approval for Dupixent in treating prurigo nodularis
Tickers: SNY, REGN
Executed On: Dec 02, 2022 at 10:00 AM EST
A First look at the new approval for Dupixent in treating prurigo nodularis
Tickers: SNY, REGN
Executed On: Nov 30, 2022 at 02:00 PM EST
A second look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: INCY, ABBV, JNJ, SNY
Executed On: Oct 28, 2022 at 10:30 AM EDT
A look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: ABBV, JNJ, SNY, INCY
Executed On: Oct 26, 2022 at 12:00 PM EDT
Discussing the P2 acelERA BC study of Giredestrant in patients with ER+, HER2– locally advanced/metastatic breast cancer and the AMEERA-3 Phase 2 study of amcenestrant in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Tickers: SNY, RHHBY, GILD, AZN, DSKYN
Executed On: Oct 04, 2022 at 10:00 AM EDT
A third look at the use and clinical efficacy of Hyaluronic acid for patients with osteoarthritis and the current treatment landscape
Ticker: SNY
Executed On: Sep 23, 2022 at 11:00 AM EDT
A second look at the use and clinical efficacy of Hyaluronic acid for patients with osteoarthritis and the current treatment landscape
Tickers: SNY, PCRX
Executed On: Aug 31, 2022 at 05:00 PM EDT
A Fourth View: Examining the potential of Haduvio in prurigo nodularis with a focus on the recent data from the P2b/3 PRISM trial
Tickers: TRVI, REGN, SNY
Executed On: Aug 30, 2022 at 12:00 PM EDT
A Third View: Examining the potential of Haduvio in prurigo nodularis with a focus on the recent data from the P2b/3 PRISM trial
Tickers: TRVI, REGN, SNY
Executed On: Aug 22, 2022 at 12:00 PM EDT
A third look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, ARWR, NVS, IONS, REGN, SNY
Executed On: Aug 17, 2022 at 04:30 PM EDT
A Second View: Examining the potential of Haduvio in prurigo nodularis with a focus on the recent data from the P2b/3 PRISM trial
Tickers: TRVI, SNY, REGN
Executed On: Aug 17, 2022 at 10:00 AM EDT
A Third View: Discussing the use and potential of Rezurock for treatment of Graft vs. Host disease (cGVHD)
Ticker: SNY
Executed On: Mar 02, 2022 at 02:00 PM EST
A Second View: Discussing the use and potential of Rezurock for treatment of Graft vs. Host disease (cGVHD)
Ticker: SNY
Executed On: Mar 01, 2022 at 10:00 AM EST
Discussing the use and potential of Rezurock for treatment of Graft vs. Host disease (cGVHD)- 1st Look
Ticker: SNY
Executed On: Feb 28, 2022 at 05:15 PM EST

Upcoming & Overdue Catalysts (SNY)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (SNY)

Don’t see a strategic initiative related to the company you care about? Create your own!